Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CFO Matt Abernethy sold 1,178 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $90.00, for a total value of $106,020.00. Following the sale, the chief financial officer now owns 1,947 shares in the company, valued at $175,230. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Neurocrine Biosciences stock traded down $2.38 during mid-day trading on Friday, reaching $84.59. 14,604 shares of the stock traded hands, compared to its average volume of 884,409. The stock has a market cap of $7.82 billion, a PE ratio of -51.93, a price-to-earnings-growth ratio of 22.06 and a beta of 0.90. Neurocrine Biosciences, Inc. has a 12-month low of $68.22 and a 12-month high of $126.98.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Monday, November 5th. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.04. The company had revenue of $151.80 million during the quarter, compared to analysts’ expectations of $151.51 million. Neurocrine Biosciences had a return on equity of 2.54% and a net margin of 2.40%. Neurocrine Biosciences’s revenue for the quarter was up 149.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.13) earnings per share. Equities research analysts anticipate that Neurocrine Biosciences, Inc. will post 0.19 EPS for the current fiscal year.

Several equities research analysts recently weighed in on NBIX shares. Morgan Stanley started coverage on Neurocrine Biosciences in a research report on Monday, September 10th. They set an “overweight” rating and a $145.00 price target on the stock. Oppenheimer set a $140.00 price target on Neurocrine Biosciences and gave the stock a “buy” rating in a research note on Tuesday, September 4th. ICAP decreased their price target on Neurocrine Biosciences from $140.00 to $128.00 and set an “outperform” rating for the company in a research note on Tuesday, September 4th. Cantor Fitzgerald started coverage on Neurocrine Biosciences in a research report on Wednesday, August 22nd. They set an “overweight” rating and a $150.00 price objective for the company. Finally, BidaskClub cut Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research report on Saturday, September 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seventeen have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $124.88.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Rehmann Capital Advisory Group boosted its stake in shares of Neurocrine Biosciences by 54.7% in the third quarter. Rehmann Capital Advisory Group now owns 557 shares of the company’s stock worth $68,000 after acquiring an additional 197 shares during the period. Marshall Wace LLP purchased a new position in Neurocrine Biosciences during the 3rd quarter worth $9,895,000. Great Lakes Advisors LLC purchased a new position in Neurocrine Biosciences during the 3rd quarter worth $9,269,000. Vanguard Group Inc. increased its holdings in Neurocrine Biosciences by 2.7% during the 3rd quarter. Vanguard Group Inc. now owns 7,772,236 shares of the company’s stock worth $955,597,000 after purchasing an additional 204,065 shares during the period. Finally, Legal & General Group Plc increased its holdings in Neurocrine Biosciences by 63.7% during the 3rd quarter. Legal & General Group Plc now owns 65,165 shares of the company’s stock worth $8,012,000 after purchasing an additional 25,365 shares during the period. Institutional investors and hedge funds own 96.88% of the company’s stock.

WARNING: This story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.watchlistnews.com/neurocrine-biosciences-inc-nbix-cfo-matt-abernethy-sells-1178-shares-of-stock/2667950.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.

See Also: Market Capitalization

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.